October 23, 2015
...AND CHEAPER...:
How Turing's Controversial $750 Pill Could be Eclipsed by a $1 Rival (Eric Pianin, October 23, 2015, Fiscal Times)
While he has been roundly ridiculed by presidential candidates, health care advocates and others as the poster child for corporate greed and bad behavior, Shkreli may have just taken an even bigger hit - to his wallet.Imprimis Pharmaceuticals, a San Diego-based company, said this week that it could make a "close, customized version" of the drug for $1 a pill, according to NBC News. If Imprimis makes good on its threat, then Shkreli probably wasted $55 million in acquiring the rights to the drug from Impax Laboratory last August.
Posted by Orrin Judd at October 23, 2015 6:03 PM
Tweet